BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 26345996)

  • 21. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
    Chen L; Li C; Zhu Y
    Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
    Wu W; Bi C; Credille KM; Manro JR; Peek VL; Donoho GP; Yan L; Wijsman JA; Yan SB; Walgren RA
    Clin Cancer Res; 2013 Oct; 19(20):5699-710. PubMed ID: 23989980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro.
    Dai Y; Siemann DW
    Mol Cancer Ther; 2010 Jun; 9(6):1554-61. PubMed ID: 20515943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
    Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
    Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nobiletin inhibits invasion and migration of human nasopharyngeal carcinoma cell lines by involving ERK1/2 and transcriptional inhibition of MMP-2.
    Chien SY; Hsieh MJ; Chen CJ; Yang SF; Chen MK
    Expert Opin Ther Targets; 2015 Mar; 19(3):307-20. PubMed ID: 25563790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
    Luo F; Lu FT; Qiu MZ; Zhou T; Ma WJ; Luo M; Zeng KM; Luo QY; Pan WT; Zhang L; Xia ZF; Zhang ZH; Cao JX; Zhao HY; Zhang L; Yang DJ
    Cell Death Dis; 2021 Aug; 12(8):772. PubMed ID: 34354046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
    Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
    Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
    [No Abstract]   [Full Text] [Related]  

  • 29. MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells.
    Liu T; Li Q; Sun Q; Zhang Y; Yang H; Wang R; Chen L; Wang W
    Biochem Biophys Res Commun; 2014 Jun; 449(1):49-54. PubMed ID: 24802404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.
    Qian CN; Guo X; Cao B; Kort EJ; Lee CC; Chen J; Wang LM; Mai WY; Min HQ; Hong MH; Vande Woude GF; Resau JH; Teh BT
    Cancer Res; 2002 Jan; 62(2):589-96. PubMed ID: 11809714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1.
    Yin P; Song G; Jiang Z
    Cancer Chemother Pharmacol; 2018 May; 81(5):863-872. PubMed ID: 29536130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    He J; Cai L; Chen Y; He Y; Wang M; Tang J; Guan H; Wang J; Peng X
    Radiother Oncol; 2018 Oct; 129(1):30-37. PubMed ID: 29519627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
    Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
    J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule inhibitor TW-37 is tolerable and synergistic with chemotherapy in nasopharyngeal carcinoma.
    Lu Y; Huang H; Yang H; Chen D; Wu S; Jiang Z; Wang R
    Cell Cycle; 2017 Jul; 16(14):1376-1383. PubMed ID: 28696828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
    Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
    J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
    Takiguchi S; Inoue K; Matsusue K; Furukawa M; Teramoto N; Iguchi H
    Int J Oncol; 2017 Jul; 51(1):184-192. PubMed ID: 28498406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.